Education
About Us
Working with TipRanks
Follow Us
Climb Bio (CLYM)
NASDAQ:CLYM
Total Valuation
Climb Bio has a market cap or net worth of $289.78M. The enterprise value is -$258.45K.
Market Cap$289.78M
Enterprise Value-$258.45K
Share Statistics
Climb Bio has 68,184,430 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding68,184,430
Owned by Insiders17.11%
Owned by Institutions56.39%
Financial Efficiency
Climb Bio’s return on equity (ROE) is -0.35 and return on invested capital (ROIC) is -38.61%.
Return on Equity (ROE)-0.35
Return on Assets (ROA)-0.34
Return on Invested Capital (ROIC)-38.61%
Return on Capital Employed (ROCE)-0.39
Revenue Per Employee0.00
Profits Per Employee-4.35M
Employee Count17
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Climb Bio is ―. Climb Bio’s PEG ratio is -0.07.
PE Ratio―
PS Ratio0.00
PB Ratio0.41
Price to Fair Value0.41
Price to FCF-5.57
Price to Operating Cash Flow-3.29
PEG Ratio-0.07
Income Statement
In the last 12 months, Climb Bio had revenue of 0.00 and earned -73.90M in profits. Earnings per share was -1.14.
Revenue0.00
Gross Profit0.00
Operating Income-82.02M
Pretax Income-73.90M
Net Income-73.90M
EBITDA-30.36M
Earnings Per Share (EPS)-1.14
Cash Flow
In the last 12 months, operating cash flow was -44.24M and capital expenditures -186.00K, giving a free cash flow of -44.43M billion.
Operating Cash Flow-44.24M
Free Cash Flow-44.43M
Free Cash Flow per Share-0.65
Dividends & Yields
Climb Bio pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.00
52-Week Price Change124.62%
50-Day Moving Average2.13
200-Day Moving Average1.69
Relative Strength Index (RSI)80.92
Average Volume (3m)721.78K
Important Dates
Climb Bio upcoming earnings date is Mar 9, 2026, After Close (Confirmed).
Last Earnings DateNov 6, 2025
Next Earnings DateMar 9, 2026
Ex-Dividend Date―
Financial Position
Climb Bio as a current ratio of 31.41, with Debt / Equity ratio of 0.34%
Current Ratio31.41
Quick Ratio31.41
Debt to Market Cap0.00
Net Debt to EBITDA2.86
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Climb Bio has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Climb Bio EV to EBITDA ratio is <0.01, with an EV/FCF ratio of <0.01.
EV to Sales0.00
EV to EBITDA<0.01
EV to Free Cash Flow<0.01
EV to Operating Cash Flow<0.01
Balance Sheet
Climb Bio has $86.90M in cash and marketable securities with $580.00K in debt, giving a net cash position of $86.32M billion.
Cash & Marketable Securities$86.90M
Total Debt$580.00K
Net Cash$86.32M
Net Cash Per Share$1.27
Tangible Book Value Per Share$4.40
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Climb Bio is $9.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$9.75
Price Target Upside122.60% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast64.81%